Widespread of ESBL- and carbapenemase GES-type genes on carbapenem-resistant Pseudomonas aeruginosa clinical isolates: a multicenter study in Mexican hospitals

ABSTRACT The in vitro activities of ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C-T), and comparators were determined for 1,774 isolates of Enterobacteriaceae and 524 isolates of Pseudomonas aeruginosa collected by 30 medical centers from the China Antimicrobial Surveillance Network (CHINET) in 2017. Antimicrobial susceptibility testing was performed by the CLSI broth microdilution method, and blaKPC and blaNDM were detected by PCR for all carbapenem-resistant Enterobacteriaceae (CRE). Ceftazidime-avibactam demonstrated potent activity against almost all Enterobacteriaceae (94.6% susceptibility; MIC50, ≤0.25 mg/liter; MIC90, ≤0.25 to >32 mg/liter) and good activity against P. aeruginosa (86.5% susceptibility; MIC50/90, 2/16 mg/liter). Among the CRE, 50.8% (189/372 isolates) were positive for blaKPC-2, which mainly existed in ceftazidime-avibactam-susceptible Klebsiella pneumoniae isolates (92.1%, 174/189). Among the CRE, 17.7% (66/372 isolates) were positive for blaNDM, which mainly existed in strains resistant to ceftazidime-avibactam (71.7%, 66/92). Ceftolozane-tazobactam showed good in vitro activity against Escherichia coli and Proteus mirabilis (MIC50/90, ≤0.5/2 mg/liter; 90.5 and 93.8% susceptibility, respectively), and the rates of susceptibility of K. pneumoniae (MIC50/90, 2/>64 mg/liter) and P. aeruginosa (MIC50/90, 1/8 mg/liter) were 52.7% and 88.5%, respectively. Among the CRE strains, 28.6% of E. coli isolates and 85% of K. pneumoniae isolates were still susceptible to ceftazidime-avibactam, but only 7.1% and 1.9% of them, respectively, were susceptible to ceftolozane-tazobactam. The rates of susceptibility of the carbapenem-resistant P. aeruginosa isolates to ceftazidime-avibactam (65.7%) and ceftolozane-tazobactam (68%) were similar. Overall, both ceftazidime-avibactam and ceftolozane-tazobactam were highly active against clinical isolates of Enterobacteriaceae and P. aeruginosa recently collected across China, and ceftazidime-avibactam showed activity superior to that of ceftolozane-tazobactam against Enterobacteriaceae, whereas ceftolozane-tazobactam showed a better effect against P. aeruginosa.

Download Full-text

Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates

International Journal of Antimicrobial Agents ◽

10.1016/j.ijantimicag.2015.01.005 ◽

2015 ◽

Vol 45 (5) ◽

pp. 556-557 ◽

Cited By ~ 7

Author(s):

Benjaporn Kunakonvichaya ◽

Krit Thirapanmethee ◽

Piyatip Khuntayaporn ◽

Preecha Montakantikul ◽

Mullika Traidej Chomnawang

Keyword(s):

Pseudomonas Aeruginosa ◽

Synergistic Effects ◽

Clinical Isolates ◽

Carbapenem Resistant

Download Full-text

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.01282-16 ◽

2016 ◽

Vol 60 (10) ◽

pp. 6407-6410 ◽

Cited By ~ 27

Author(s):

Gabriel Torrens ◽

Gabriel Cabot ◽

Alain A. Ocampo-Sosa ◽

M. Carmen Conejo ◽

Laura Zamorano ◽

...

Keyword(s):

Pseudomonas Aeruginosa ◽

Multidrug Resistance ◽

Multicenter Study ◽

Bloodstream Infections ◽

Resistance Mechanisms ◽

Clinical Isolates ◽

Complete Collection ◽

Content Type ◽

Isogenic Mutants

ABSTRACTThe activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190Pseudomonas aeruginosaclinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16P. aeruginosaPAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.

Download Full-text

Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among Pseudomonas aeruginosa clinical isolates in Brazil

The Brazilian Journal of Infectious Diseases ◽

10.1016/j.bjid.2016.10.008 ◽

2017 ◽

Vol 21 (1) ◽

pp. 57-62 ◽

Cited By ~ 7

Author(s):

Eloiza Helena Campana ◽

Danilo Elias Xavier ◽

Fernanda Villas-Boas Petrolini ◽

Jhonatha Rodrigo Cordeiro-Moura ◽

Maria Rita Elmor de Araujo ◽

...

Keyword(s):

Pseudomonas Aeruginosa ◽

Clinical Isolates ◽

Carbapenem Resistant

Download Full-text

In-vitro activity of Fosfomycin against clinical isolates of carbapenem resistant Acinetobacter baumannii complex and Pseudomonas aeruginosa at a South African academic hospital

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2016.02.245 ◽

2016 ◽

Vol 45 ◽

pp. 92 ◽

Cited By ~ 1

Author(s):

A.A. Hoosen ◽

K. Baba

Keyword(s):

Pseudomonas Aeruginosa ◽

Acinetobacter Baumannii ◽

South African ◽

Vitro Activity ◽

Clinical Isolates ◽

In Vitro Activity ◽

Academic Hospital ◽

Carbapenem Resistant ◽

Acinetobacter Baumannii Complex

Download Full-text

Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems

Journal of Medical Microbiology ◽

10.1099/jmm.0.46816-0 ◽

2007 ◽

Vol 56 (1) ◽

pp. 66-70 ◽

Cited By ~ 24

Author(s):

Spyros Pournaras ◽

Alexandros Ikonomidis ◽

Antonios Markogiannakis ◽

Nicholas Spanakis ◽

Antonios N. Maniatis ◽

...

Keyword(s):

Pseudomonas Aeruginosa ◽

Population Analysis ◽

Growth Curves ◽

Clinical Isolates ◽

Lag Phase ◽

Carbapenem Resistant ◽

One Step ◽

Agar Dilution ◽

Resistant Mutants ◽

Selection Of

Fourteen apparently carbapenem-susceptible Pseudomonas aeruginosa clinical isolates that exhibited colonies within the inhibition zone around carbapenem discs were analysed. MICs of carbapenems were determined and the isolates were genotyped by PFGE. Population analysis, one-step selection of carbapenem-resistant mutants and growth curves of progenitors and carbapenem-resistant subpopulations were performed. Agar dilution MICs of imipenem and meropenem ranged from 0.5 to 4 mg l−1 and from 0.25 to 2 mg l−1, respectively. Population analysis confirmed subpopulations that grew in concentrations of up to 18 mg l−1 and 12 mg l−1 of imipenem and meropenem, respectively, at frequencies ranging from 6.9×10−5 to 1.1×10−7, suggesting that they might not be detected by standard agar dilution MIC testing. The minority subpopulations exhibited MICs for imipenem ranging from 10 to 20 mg l−1 and for meropenem from 4 to 14 mg l−1. The one-step 8 mg l−1 selection of imipenem-resistant mutants test showed growth in all isolates at frequencies ranging from 3.8×10−4 to 5.1×10−7. Growth curves revealed a prolonged lag phase and a short exponential phase for the heterogeneous subpopulations compared with their respective native subpopulations. These findings may be indicative that the use of carbapenems can lead to selection of P. aeruginosa resistant subpopulations that subsequently cause infections and result in treatment failure.

Download Full-text

New Delhi Metallo-β-lactamase (NDM)-mediated Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolates in Sudan

South Asian Journal of Research in Microbiology ◽

10.9734/sajrm/2018/v1i3775 ◽

2018 ◽

pp. 1-5

Author(s):

Salma Elnour Rahma Mohamed ◽

Alfadil Alobied ◽

Mohamed Ibrahim Saeed ◽

Wafa Mohamed Hussien

Keyword(s):

Pseudomonas Aeruginosa ◽

Teaching Hospital ◽

Carbapenem Resistance ◽

Clinical Isolates ◽

Diffusion Method ◽

New Delhi ◽

Army Hospital ◽

Carbapenem Resistant ◽

Wide Range ◽

Data Documentation

Carbapenem resistance mediated by NDM is particularly gruesome as this carbapenemase can hydrolyze a wide range of β-lactam antibiotics. Aim: This study aims to detect NDM mediated carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. Materials and Methods: 50 multi-drug resistant clinical urinary isolates of Pseudomonas aeruginosa from three major hospitals in Khartoum state Sudan; Khartoum Teaching Hospital, Medical Army Hospital and Omdurman teaching hospital, in period from July 2016 to September 2017, were investigated for carbapenem resistance using standard disc diffusion method and underwent real-time PCR to detect carbapenem resistance gene blaNDM. Data were analyzed using IBM SPSS. Results: 60% were positive for the blaNDM, 82% were resistant to Imipenem and 75% of the samples were resistant to Meropenem. Conclusion: The emergence of carbapenem resistance is a global problem that requires earnest attention. To make the suitable preventive measures, the emergence of these genes must be monitored closely. Our findings revealed that carbapenem-resistant due to the gene blaNDM is accounted for 60% of the cases, and due to lack of proper data documentation about the emergence of this gene in Sudan, these cases to the best of our knowledge are the first to be reported in Sudan.

Download Full-text